key: cord-0682315-zqrcnbpp
authors: Hassoun, Ameer; Brady, KeriAnne; Arefi, Rojin; Trifonova, Irina; Tsirilakis, Kalliope
title: Vaping Associated Lung Injury During COVID-19 Multisystem Inflammatory Syndrome Outbreak
date: 2020-12-11
journal: J Emerg Med
DOI: 10.1016/j.jemermed.2020.12.005
sha: 1a04648aaef8ff84d5dfaf95e0f1432ee8a8a9f0
doc_id: 682315
cord_uid: zqrcnbpp

Background E-cigarette, or Vaping, Product Use–Associated Lung Injury (EVALI) is a complex inflammatory syndrome predominantly seen in adolescents and young adults. The clinical and laboratory profile can easily mimic infectious and non-infectious conditions. The exclusion of these conditions is essential to establish the diagnosis. Recently, the novel coronavirus disease 2019 (COVID-19) pandemic introduced the multisystem inflammatory syndrome in children (MIS-C). MIS-C knowledge is evolving. The current criteria to establish the diagnosis are not specific and have overlapping features with EVALI, making the accurate diagnosis a clinical challenge during continued COVID-19 transmission within the community. Case Report Three young adults evaluated at our emergency department for prolonged fever, gastrointestinal and respiratory complaints that initially assessed for possible MIS-C due to epidemiological links to COVID-19, and eventually were diagnosed with EVALI. The clinical, laboratory and radiological characteristics of both entities are explored, as well as the appropriate medical management. Why Should an Emergency Physician Be Aware of This? : Physician awareness of overlapping and differentiating EVALI and MIS-C features is essential to direct appropriate diagnostic evaluation and medical management of adolescents and young adults presenting with systemic inflammatory response during the unfolding pandemic of COVID-19.

In mid-2019, The United States experienced a surge in E-cigarette, or Vaping, Product Use-Associated 23

Lung Injury (EVALI) hospitalizations or deaths. As of February 18, 2020, more than 2,800 cases were 24 reported to the Centers for Disease Control and Prevention (CDC) from 50 States, half of which are in 25 patients 13-24 years old. 1 By March 2020, novel coronavirus disease 2019 (COVID-19) spread 26 within the United States with the initial epicenter of disease in New York City. Over the next few 27 months, the COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) 28 emerged as a new condition. 2 Reports from Europe described the initial wave of cases presenting 29 with clinical findings reflecting a spectrum of inflammatory effects on multiple organ systems in 30 children. 3 -4 Recently, the COVID-19 associated multisystem inflammatory syndrome in adults 31 (MIS-A) extended the definition of MIS-C to adults beyond 21 years of age. 5 

The overlap of symptomatology and laboratory findings constitute a diagnostic challenge to 33 frontline pediatricians, especially during continued COVID-19 community transmission. Our 34 knowledge of both conditions is evolving. Early recognition is imperative to direct appropriate 35 management. We report three patients evaluated for possible MIS sedimentation rate), D-dimer, and fibrinogen were elevated. COVID-19 polymerase chain 49 reaction (PCR) and serology were both negative. An abdominal sonogram was unremarkable. 50

The decision was made to admit her for further evaluation and intravenous fluid hydration. 51

Upon admission, a history of vaping tetrahydrocannabinol (THC) was elicited. On the first night 52 of admission, the patient had an episode of SOB with transient oxygen desaturation to 92% after 53 a vomiting episode. A chest radiograph (CXR) revealed a mild left peri-hilar opacity. Given her 54 vaping history, a chest computed tomography scan (CT) was performed, which showed bilateral 55 ground-glass opacities, with consolidation in the left lower lobe (Figure 1 ). The patient was 56 started on methylprednisolone, ceftriaxone, and azithromycin. The patient was discharged three 57 days after admission with a complete tapering course of prednisone and azithromycin. Follow-up 58 with the pediatric pulmonology clinic confirmed the rapid resolution of symptoms and 59 improvement in inflammatory markers. Outpatient pulmonary function testing revealed a mild 60 lung restriction with moderate diffusion limitation, with improvement after two months. 61 62 Case 2: A 19-year-old male with a history of asthma presented with one week of nausea, 63 lightheadedness, and anorexia. He had a mild sore throat and cough a few days prior, which 64 spontaneously resolved. He denied vomiting, diarrhea, abdominal pain, shortness of breath, 65 fever, or COVID-19 exposure. He admitted vaping both nicotine and THC oils. Clinically, the 66 patient was febrile, tachycardic, tachypneic, and hypoxic (Table 1) . He had a mildly 67 J o u r n a l P r e -p r o o f erythematous posterior oropharynx and dry mucous membranes. Chest auscultation revealed a 68 bilateral decrease in breath sounds without accessory muscle use. In addition, the patient 69 experienced tenderness and guarding in the right lower abdomen. 70

The differential diagnosis at that time included EVALI, pneumonia, appendicitis, and MIS-C. 71

Labs were significant for an elevated WBC, erythrocyte sedimentation rate (ESR), and C-72 reactive protein (CRP). His COVID-19 PCR was negative. A rapid Group A streptococcus test 73 was positive. CXR revealed mildly prominent interstitial lung markings, worse on the right. A 74 contrast-enhanced CT of the abdomen and pelvis was performed to evaluate for appendicitis. 75

The lung bases on this scan, had bilateral ground-glass opacities with reticulation and 76 interlobular septal thickening, most prominently at the right lower lobe and left lingula ( Figure  77 2). The appendix was normal. While in the PED, the patient became hypoxic to 88% and 78 remained tachypneic; he was given 4L of O2 via NC. He was started on ceftriaxone, 79 methylprednisolone, and azithromycin and was admitted to the inpatient floor. He was weaned 80 to room air within three days of hospitalization, after which he signed out against medical advice 81 with a complete course of azithromycin and prednisone. This patient did not follow up after 82 leaving the hospital. 83 84 Case 3: A healthy 21-year-old male presented with one week of fevers up to 38.8 C, with 85 associated body aches, nausea, throat pain, and epigastric abdominal pain radiating to the chest. 86

He had a sick contact with COVID-19 two weeks before the presentation and had a negative 87 COVID-19 PCR swab one week prior. He denied cough, shortness of breath, vomiting, diarrhea, 88 or rash. He initially denied any use of tobacco, alcohol, or drugs. On physical examination, he 89 was febrile, tachycardic, and tachypneic (Table 1) (Table 2 ). 8 -9 Six months prior, the United States experienced the E-cigarette, or 117

Vaping, Product Use-Associated Lung Injury outbreak. Studies suggested that E-cigarette, or 118 vaping products containing vitamin E acetate, usually from informal sources ( e.g., family, 119 friends, or drug dealers), can trigger lung injury and systemic inflammatory response. 10 -11 120 EVALI patients usually experience fever, cough, shortness of breath, nausea, vomiting, diarrhea, 121 or abdominal pain. Hypoxia, tachypnea, or tachycardia are also common (Table 3) . MIS-C 122 patients also present with similar symptoms. 90% of MIS-C patients experience gastrointestinal 123 symptoms, and more than 60% suffer respiratory system abnormalities (cough, shortness of 124 breath, pneumonia, or acute respiratory distress syndrome), which could indicate a mixed illness 125 of acute COVID-19 and MIS-C. 12 The similarities of the clinical picture between COVID-19 and 126 EVALI 13 Obtaining a social history of vaping or electronic cigarettes use can be critical to consider 134 EVALI in the initial clinical evaluation. 14 In two of our patients, EVALI was not considered in 135 the initial differential as the exposure history was obtained later in the course. Other 136 J o u r n a l P r e -p r o o f discriminatory features between the two conditions include cardiovascular involvement, as 86% 137

of MIS-C patients suffer a form of cardiac injury (e.g., shock, abnormal blood levels of troponin 138 or pro-brain natriuretic peptide). 9 • CXR and/or CT scans: bilateral diffuse ground-glass opacities • Elevated C-reactive protein • Elevated Erythrocyte sedimentation rate • Positive urine drug screen for Δ-9tetrahydrocannabinol or its metabolites • Exclusion of viral or bacterial etiology J o u r n a l P r e -p r o o f 

Multisystem inflammatory syndrome in U.S. children and adolescents

Hyperinflammatory shock in children during COVID-19 pandemic

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States

Into the eye of the cytokine storm

Vaping-Induced Acute Lung Injury

COVID-19)

Multisystem inflammatory syndrome in children and adolescents with COVID-19. World Health Organization website

Lung Injury Response Laboratory Working Group. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI

Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury -United States

COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States

A 16-Year-Old Boy With Cough and Fever in the Era of COVID-19

Notes from the Field: E-cigarette, or Vaping, Product Use-Associated Lung Injury Cases During the COVID-19 Response -California

COVID-19) Pneumonia: What Radiologists Need to Know